• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    11/29/23 4:31:06 PM ET
    $ACRX
    $ADIL
    $ADXN
    $CPHI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACRX alert in real time by email

    Gainers

    • Adial Pharmaceuticals (NASDAQ:ADIL) shares increased by 30.5% to $2.78 during Wednesday's after-market session. The market value of their outstanding shares is at $3.3 million.
    • Dyadic International (NASDAQ:DYAI) shares rose 9.35% to $1.87. The market value of their outstanding shares is at $53.8 million.
    • AcelRx Pharmaceuticals (NASDAQ:ACRX) shares increased by 9.34% to $0.75. The market value of their outstanding shares is at $12.6 million.
    • Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 9.33% to $4.8. The market value of their outstanding shares is at $4.7 million.
    • Revelation Biosciences (NASDAQ:REVB) stock rose 9.2% to $0.8. The company's market cap stands at $5.0 million.
    • NexImmune (NASDAQ:NEXI) shares rose 9.03% to $1.81. The market value of their outstanding shares is at $1.9 million.

    Losers

    • China Pharma Holding (AMEX:CPHI) shares decreased by 10.6% to $0.12 during Wednesday's after-market session. The market value of their outstanding shares is at $3.7 million.
    • Vivos Therapeutics (NASDAQ:VVOS) stock declined by 9.76% to $37.0. The company's market cap stands at $44.2 million.
    • Altamira Therapeutics (NASDAQ:CYTO) shares fell 8.23% to $0.59. The company's market cap stands at $4.7 million.
    • Kintara Therapeutics (NASDAQ:KTRA) stock decreased by 6.33% to $0.37.
    • Addex Therapeutics (NASDAQ:ADXN) shares fell 6.2% to $5.3. The company's market cap stands at $4.3 million. As per the news, the Q3 earnings report came out today.
    • LumiraDx (NASDAQ:LMDX) stock fell 5.88% to $0.11. The market value of their outstanding shares is at $35.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRX
    $ADIL
    $ADXN
    $CPHI

    CompanyDatePrice TargetRatingAnalyst
    Dyadic International Inc.
    $DYAI
    10/23/2025$3.00Buy
    H.C. Wainwright
    Dyadic International Inc.
    $DYAI
    9/8/2025Buy
    Craig Hallum
    Adial Pharmaceuticals Inc
    $ADIL
    11/14/2024$8.00Buy
    Rodman & Renshaw
    Addex Therapeutics Ltd
    $ADXN
    7/31/2024$30.00Neutral → Buy
    H.C. Wainwright
    Dyadic International Inc.
    $DYAI
    7/18/2022Buy → Neutral
    Dawson James
    LumiraDx Limited
    $LMDX
    3/11/2022$13.00 → $9.00Outperform
    Raymond James
    NexImmune Inc.
    $NEXI
    2/22/2022$21.00 → $13.00Outperform
    Raymond James
    Revelation Biosciences Inc.
    $REVB
    2/17/2022$12.00Buy
    Roth Capital
    More analyst ratings

    $ACRX
    $ADIL
    $ADXN
    $CPHI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners

    LITTLETON, Colo., April 07, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea ("OSA"), announced that it has closed on a private placement with V-Co Investors 3 LLC ("V-Co 3"), an affiliate of New Seneca Partners Inc. ("Seneca"). Gross proceeds of $2.25 million including the conversion of a previously announced bridge note of $1.4 million (prior to giving effect to an associated original issue discount). The private placement closed on March 31, 2026. This

    4/7/26 8:45:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market

    Insurance Coverage on Vivos Appliances and Treatment Now Available to a Significant Number of Nevada Patients Previously Unable to Access Coverage Concurrently, Vivos Implements Cost Reduction Initiatives Related to Legacy Business Model to Focus on Scaling its Medical Affiliation Distribution Model LITTLETON, Colo., March 26, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (OSA), today announced that physician-owned professional entities supported by t

    3/26/26 8:45:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

    – Closes Private Placement Financing of Up to $104.5 Million – Secures Orphan Drug Designations for QRX003 for Netherton Syndrome (NS) in the U.S. and Europe  – Advances Proposed Expedited Regulatory Approval Pathways in Japan and Saudi Arabia and Secures Fast Track Designation in the U.S. for QRX003 for NS Subsequent to the End of Q4 – Reports Continued Clinical Progress for QRX003 in Netherton Syndrome Clinical Studies including Data Supporting Longer Term Durable Treatment Effect and Safety Profile – Pediatric NS Study Expanded to 7 Children Now Actively Treated with QRX003, Largest Cohort of This Age Group Ever Studied – Ongoing Clinical Data Continues to Support Development of QR

    3/26/26 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $ACRX
    $ADIL
    $ADXN
    $CPHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider V-Co Investors 3 Llc

    3 - Vivos Therapeutics, Inc. (0001716166) (Issuer)

    4/10/26 4:54:28 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Anderson J. Kermit

    4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)

    4/9/26 5:00:09 PM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Goodman Tony

    4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)

    4/9/26 5:00:10 PM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $ADIL
    $ADXN
    $CPHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Langer Dennis bought $128,640 worth of ADSs (15,152 units at $8.49), increasing direct ownership by 1,515,200% to 15,153 units (SEC Form 4)

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    10/15/25 5:15:20 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    President and COO Hazelton Joseph P bought $24,700 worth of shares (26,000 units at $0.95), increasing direct ownership by 20% to 155,340 units (SEC Form 4)

    4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

    8/5/25 5:00:10 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Operating Officer Carter Denise P. bought $250,000 worth of Ordinary Shares (555,556 units at $0.45), increasing direct ownership by 1,180% to 602,648 units (SEC Form 4)

    4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)

    12/27/24 5:17:23 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $ACRX
    $ADIL
    $ADXN
    $CPHI
    SEC Filings

    View All

    Adial Pharmaceuticals Inc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)

    4/9/26 5:00:08 PM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)

    4/3/26 4:05:33 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by China Pharma Holdings Inc.

    10-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)

    4/1/26 4:15:23 PM ET
    $CPHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $ADIL
    $ADXN
    $CPHI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Dyadic International with a new price target

    H.C. Wainwright resumed coverage of Dyadic International with a rating of Buy and set a new price target of $3.00

    10/23/25 7:06:50 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Craig Hallum initiated coverage on Dyadic International

    Craig Hallum initiated coverage of Dyadic International with a rating of Buy

    9/8/25 8:52:07 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rodman & Renshaw initiated coverage on Adial Pharmaceuticals with a new price target

    Rodman & Renshaw initiated coverage of Adial Pharmaceuticals with a rating of Buy and set a new price target of $8.00

    11/14/24 7:21:37 AM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $ADIL
    $ADXN
    $CPHI
    Financials

    Live finance-specific insights

    View All

    Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress

    Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic's production platform, with Dyadic eligible to receive a share of profits from product salesExpanded strategic collaboration with Fermbox Bio, including the launch of animal-origin-free recombinant DNase I (RNase-free) as the first commercialized product under the expanded partnershipSigned an OEM distribution agreement with IBT Bioservices to commercialize Dyadic's recombinant DNase I and transferrin for research and cell culture applications through IBT's global distribution channelsEntered a development and commercialization agreement with BRIG Bio to produce animal-free bovine alpha-

    3/25/26 4:51:29 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026

    JUPITER, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the year ended December 31, 2025 and host a corporate update conference call on Wednesday, March 25, 2026. Conference Call Information Date: Wednesday, March 25, 2026 Time: 5:00 p.m. Eastern

    3/11/26 4:10:00 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its financial results for the three-month and nine-month periods ended September 30, 2025, and provided a corporate update. "We continue to make great progress with our GABAB positive allosteric modulator (PAM) candidate in chronic cough following demonstration of robust anti-tussive activity in multiple chronic cough preclinical models earlier in the year as well as advancing dipraglurant for post-stro

    12/4/25 1:00:00 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $ADIL
    $ADXN
    $CPHI
    Leadership Updates

    Live Leadership Updates

    View All

    Addex Appoints Bank of New York Mellon as Depositary Bank

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 23, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced the appointment the Bank of New-York Mellon (BNY) as its new ADS depositary agent. This change is expected to become effective on October 6, 2025.  The appointment of BNY has no impact on the fees paid by ADS holders. At the effective date, no action will be required by the ADS holders. About Addex Therapeutics Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a

    9/23/25 1:00:00 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy

    ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appointment of its new Chief Financial Officer as the Company advances its lead product candidate, QRX003, through pivotal clinical studies and prepares for potential commercialization. Quoin has appointed Sally Lawlor, BCL, FCA, as its new Chief Financial Officer, effective immediately. Ms. Lawlor is an accomplished finance executive with over 20 years of experience in financial leadership roles in public and private companies as well as a Big Four accounting fir

    8/18/25 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Vivos Therapeutics Adds to Management Team to Support Expansion and Growth

    LITTLETON, Colo., July 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ:VVOS) ("Vivos" or the "Company"), a pioneering medical technology company revolutionizing the treatment of obstructive sleep apnea (OSA) and snoring, today announced the appointments of Michael (Mike) E. Bruhn as its Executive Vice President of Business Operations Integration, and Dr. Terry Jones as its new Senior Vice President of Human Resources. These hires demonstrate Vivos' commitment to the successful implementation and expansion of its new sleep testing center and direct patient treatment operations, highlighted by Vivos' recent acquisition of The Sleep Center of Nevada and Vivos' ongoing, active e

    7/30/25 8:45:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $ACRX
    $ADIL
    $ADXN
    $CPHI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd.

    SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

    11/14/24 7:23:29 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vivos Therapeutics Inc.

    SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)

    11/14/24 4:49:30 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vivos Therapeutics Inc.

    SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)

    11/14/24 4:05:24 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care